Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-23,400
Closed -$1.55M 449
2025
Q4
$1.55M Buy
+23,400
New +$1.51M 0.03% 336
2025
Q3
Sell
-7,500
Closed -$655K 571
2025
Q2
$655K Buy
+7,500
New +$588K 0.02% 538
2025
Q1
Sell
-10,900
Closed -$848K 842
2024
Q4
$848K Buy
+10,900
New +$807K 0.02% 462
2024
Q3
Sell
-2,400
Closed -$272K 947
2024
Q2
$272K Buy
+2,400
New +$303K 0.01% 811
2024
Q1
Sell
-7,500
Closed -$931K 547
2023
Q4
$931K Sell
7,500
-23,700
-76% -$2.42M 0.02% 495
2023
Q3
$2.91M Buy
31,200
+29,600
+1,850% +$3.34M 0.03% 296
2023
Q2
$206K Sell
1,600
-3,000
-65% -$363K ﹤0.01% 815
2023
Q1
$534K Sell
4,600
-1,900
-29% -$213K 0.01% 636
2022
Q4
$736K Sell
6,500
-5,100
-44% -$560K 0.02% 488
2022
Q3
$934K Buy
11,600
+7,300
+170% +$618K 0.02% 564
2022
Q2
$320K Sell
4,300
-2,900
-40% -$265K 0.01% 735
2022
Q1
$921K Sell
7,200
-1,600
-18% -$175K 0.03% 364
2021
Q4
$1.18M Sell
8,800
-9,200
-51% -$1.32M 0.03% 297
2021
Q3
$2.46M Buy
18,000
+6,800
+61% +$858K 0.08% 191
2021
Q2
$1.2M Buy
11,200
+2,800
+33% +$269K 0.05% 374
2021
Q1
$755K Buy
+8,400
New +$789K 0.03% 510
2020
Q4
Sell
-2,000
Closed -$204K 650
2020
Q3
$204K Sell
2,000
-1,600
-44% -$167K 0.02% 556
2020
Q2
$365K Buy
+3,600
New +$322K 0.03% 366

Other funds holding DXCM

Maven Securities's DXCM Position: Q1 2026 in Review

Maven Securities sold out of DexCom (DXCM) in Q1 2026, closing a stake of 26,696 shares — an estimated $1.77M sold.

Maven Securities first reported a position in DXCM in Q3 2018 and held it in 12 quarters. The position peaked at $1.85M in Q4 2020. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Maven Securities reported no remaining DexCom position as of Q1 2026 after selling out during the quarter.
  • Maven Securities sold 26,696 DexCom shares in Q1 2026, an estimated $1.77M.
  • Maven Securities first reported a position in DexCom in Q3 2018 and held it in 12 quarters.
  • Maven Securities's DexCom position peaked at $1.85M in Q4 2020.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Maven Securities's 13F filing for Q1 2026, filed 15 May 2026.